Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Regorafenib | Correction

Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer

Authors: Elif Şenocak Taşçı, Başak Oyan, Özlem Sönmez, Arda Ulaş Mutlu, Muhammed Mustafa Atcı, Abdullah Sakin, İrem Öner, Havva Yeşil Çınkır, Melek Karakurt Eryılmaz, Dilek Çağlayan, Onur Yazdan Balçık, Nail Paksoy, Senem Karabulut, Derya Kıvrak Salim, Cemil Bilir, Miraç Özen, Melike Özçelik, Ali Arıcan, Baran Akagündüz, Ali İnal, Dinçer Aydın, Leyla Özer, Ahmet Gülmez, Nazım Serdar Turhal, Selin Aktürk Esen, Efnan Algın, Sinem Akbaş, Yakup İriağaç, Teoman Şakalar, Çağlar Ünal, Özlem Er, Şaban Seçmeler, Mustafa Bozkurt

Published in: BMC Cancer | Issue 1/2024

Login to get access

Excerpt

Correction: BMC Cancer 24, 16 (2024)
Metadata
Title
Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer
Authors
Elif Şenocak Taşçı
Başak Oyan
Özlem Sönmez
Arda Ulaş Mutlu
Muhammed Mustafa Atcı
Abdullah Sakin
İrem Öner
Havva Yeşil Çınkır
Melek Karakurt Eryılmaz
Dilek Çağlayan
Onur Yazdan Balçık
Nail Paksoy
Senem Karabulut
Derya Kıvrak Salim
Cemil Bilir
Miraç Özen
Melike Özçelik
Ali Arıcan
Baran Akagündüz
Ali İnal
Dinçer Aydın
Leyla Özer
Ahmet Gülmez
Nazım Serdar Turhal
Selin Aktürk Esen
Efnan Algın
Sinem Akbaş
Yakup İriağaç
Teoman Şakalar
Çağlar Ünal
Özlem Er
Şaban Seçmeler
Mustafa Bozkurt
Publication date
01-12-2024
Publisher
BioMed Central
Keyword
Regorafenib
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-11863-0

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine